{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:40:23Z","timestamp":1779889223976,"version":"3.53.1"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study reports health\u2010related quality of life (HRQL) among newly\u2010diagnosed immunoglobulin light\u2010chain (AL) patients (<jats:italic>n<\/jats:italic>\u00a0=\u2009914) treated with a bortezomib\u2010based regimen and its association with response depth and survival. Haematologic response\/HRQL were assessed over 24\u2009months in an ongoing, prospective study. HRQL change was calculated across haematologic\/cardiac response levels. The relationship between baseline HRQL and survival was evaluated by the Cox proportional\u2010hazard model (PH). Shared\u2010random\u2010effects models (SREMs) estimated time\u2010to\u2010death conditional on current HRQL\/longitudinal HRQL trajectory. At 3\u00a0months, there was consistent decline in 5\/8 HRQL domains across all haematologic response levels. By 12\u2009months, 3\/5 declining domains improved among complete response (CR) patients. In contrast, the mean change in less\u2010than\u2010CR patients did not indicate improvement. Under the Cox PH, having a baseline HRQL score five points higher than the sample mean was associated with 20% lower mortality risk. SREMs indicated a five\u2010point greater HRQL score at the event time correlated with an approximately 30% decrease in mortality risk. For each one\u2010point increase in HRQL score trajectory slope, mortality risk decreased by approximately 88%. Only CR patients had HRQL improvement, while partial response patients had less decline but no meaningful improvements. These data show the importance of HRQL serial assessments of AL patients and its importance as an end\u2010point.<\/jats:p>","DOI":"10.1111\/bjh.18645","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T23:24:06Z","timestamp":1675034646000},"page":"422-431","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light\u2010chain amyloidosis"],"prefix":"10.1111","volume":"201","author":[{"given":"Oliver","family":"Cohen","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-1819","authenticated-orcid":false,"given":"Regina","family":"Rendas\u2010Baum","sequence":"additional","affiliation":[{"name":"QualityMetric Incorporated, LLC  Johnston Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1046","authenticated-orcid":false,"given":"Kristen","family":"McCausland","sequence":"additional","affiliation":[{"name":"QualityMetric Incorporated, LLC  Johnston Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Foard","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Manwani","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-0088","authenticated-orcid":false,"given":"Sriram","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lachmann","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameem","family":"Mahmood","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Wisniowski","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[{"name":"Amyloidosis Research Consortium Inc.  Newton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rebello","sequence":"additional","affiliation":[{"name":"Amyloidosis Research Consortium Inc.  Newton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,29]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"European Medicines Agency.Committee for medicinal products for human use: Darzalex (daratumumab);2021.https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp\u2010post\u2010authorisation\u2010summary\u2010positive\u2010opinion\u2010darzalex\u2010ii\u201043\u2010ii\u201044_en.pdf. Accessed August 16 2021."},{"key":"e_1_2_10_3_1","unstructured":"U.S. Food & Drug Administration.FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis;2021.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010darzalex\u2010faspro\u2010newly\u2010diagnosed\u2010light\u2010chain\u2010amyloidosis. Accessed August 16 2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201011\u2010751628"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1917321"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20381"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010020\u201001525\u20102"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010015\u20100250\u20100"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000412\u20108"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3586.3586"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102004\u201001\u20100089"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24676"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000834"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_2_10_16_1","volume-title":"User's Manual for the SF\u201036v2 Health Survey","author":"Maruish ME","year":"2011"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1201\/b12208"},{"key":"e_1_2_10_18_1","volume-title":"Cambridge Series in Statistical and Probabilistic Mathematics","author":"Claeskens G","year":"2008"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320430047030"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eswa.2016.07.018"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","unstructured":"RizopoulosD.Joint modeling of longitudinal and survival data. R package version 1.4.2016.","DOI":"10.1002\/9781118445112.stat07849"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201012\u2010473066"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14889"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24176"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1713743"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010016\u20100564\u20102"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2015.1102131"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010021\u201002943\u2010w"},{"key":"e_1_2_10_29_1","volume-title":"ISOQOL 29th annual conference","author":"O'Connor M"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18645","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T02:55:31Z","timestamp":1692586531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,29]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/bjh.18645"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18645","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,29]]},"assertion":[{"value":"2022-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}